» Articles » PMID: 8308015

Phosphorylation of the Human Estrogen Receptor. Identification of Hormone-regulated Sites and Examination of Their Influence on Transcriptional Activity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1994 Feb 11
PMID 8308015
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

We have used a transient transfection system with a cytomegalovirus-based vector expressing high levels of biologically active human estrogen receptor (ER) in COS-1 cells to study the phosphorylation of human ER and to identify major hormone-regulated phosphorylation sites. The features of phosphorylation of the wild-type ER were very similar to those previously observed for the endogenous ER in uterine cells: The ER exhibited a basal level of phosphorylation which was increased approximately 3-4-fold by estrogen (estradiol) and by antiestrogens (hydroxytamoxifen and ICI164,384), and phosphorylation was increased to an almost similar extent by activation of either protein kinase A or C signal transduction pathways with cholera toxin plus isobutyl methylxanthine (CT+IBMX) or phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), respectively. Phosphoamino acid analysis revealed that the phosphorylation occurred exclusively on serine residues in all cases. Tryptic phosphopeptide analysis of ER, using a two-dimensional peptide mapping procedure, revealed similar patterns for ER in cells treated with estradiol, antiestrogens or TPA; with CT+IBMX treatment, the same phosphopeptides were seen, but the relative phosphorylation of the different ER phosphotryptic peptides differed. In ER deleted of the NH2-terminal A and B (A/B) domains, estrogen and antiestrogen-stimulated phosphorylations were abolished, while the phosphorylation induced by CT+IBMX was maintained. This suggests that sites of phosphorylation enhanced by estradiol and antiestrogen, but not those induced by CT+IBMX, are located in the A/B domain. These results were further confirmed by comparing the tryptic phosphopeptide patterns of wild-type and A/B-deleted receptor upon estradiol and CT+IBMX treatments, and then by site-directed mutagenesis, by substituting alanines for the serine residues in the A/B domain (Ser104, Ser106, Ser118, Ser154, and Ser167) involved in known protein kinase consensus sequences. Comparison of the tryptic phosphopeptide patterns of wild-type ER and these mutant ERs allowed us to identify serine 104 and/or serine 106 and serine 118, all three being part of a serine-proline motif, the preferred substrate of proline-directed protein kinase, as major ER phosphorylation sites. When tested with two estrogen-responsive reporter gene constructs in several cell types, the mutant S104A, S106A, S118A showed a approximately 40% reduction in transactivation activity in response to E2, while the mutants S118A and S104A, S106A alone showed a approximately 15% decrease in transactivation. Our studies identify several serines in the NH2-terminal portion of the human ER as being major hormone-regulated phosphorylation sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Deciphering the Role of BCAR3 in Cancer Progression: Gene Regulation, Signal Transduction, and Therapeutic Implications.

Moon D Cancers (Basel). 2024; 16(9).

PMID: 38730626 PMC: 11083344. DOI: 10.3390/cancers16091674.


AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer.

Kiliti A, Sharif G, Martin M, Wellstein A, Riegel A Front Endocrinol (Lausanne). 2023; 14:1250218.

PMID: 37711895 PMC: 10498919. DOI: 10.3389/fendo.2023.1250218.


CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells.

Hany D, Vafeiadou V, Picard D Sci Adv. 2023; 9(19):eadd3685.

PMID: 37172090 PMC: 10181187. DOI: 10.1126/sciadv.add3685.


Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.

Tang Y, Li J, Liu B, Ran J, Hu Z, Ouyang Q Front Endocrinol (Lausanne). 2022; 13:1075830.

PMID: 36518248 PMC: 9742482. DOI: 10.3389/fendo.2022.1075830.


Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.

Skolariki A, DCosta J, Little M, Lord S Explor Target Antitumor Ther. 2022; 3(2):172-199.

PMID: 36046843 PMC: 9400772. DOI: 10.37349/etat.2022.00078.